Suppressive effects of dehydroepiandrosterone and the nuclear factor-κB inhibitor parthenolide on corticotroph tumor cell growth and function in vitro and in vivo

Journal of Endocrinology

Volumn 188, Issue 2, 2006, Pages 321-331

  Taguchi, T ^a   Takao, T ^a   Iwasaki, Y ^a   Nishiyama, M ^a   Asaba, K ^a   Hashimoto, K ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; PARTHENOLIDE; PRASTERONE; PROOPIOMELANOCORTIN; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HYPOPHYSIS TUMOR; IN VITRO STUDY; IN VIVO STUDY; MALE; MALNUTRITION; MOUSE; MOUSE STRAIN; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CORTICOSTERONE; DEHYDROEPIANDROSTERONE; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NF-KAPPA B; PITUITARY NEOPLASMS; PRO-OPIOMELANOCORTIN; RNA, MESSENGER; RNA, NEOPLASM; SESQUITERPENES; TESTOSTERONE; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 33244491901     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06418     Document Type: Article

References (40)

1. Ambrosini G, Adida C & Altieri DC 1997 A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine 3 917-921.
2. Aoki K, Nakajima A, Mukasa K, Osawa E, Mori Y & Sekihara H 2003 Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone. Journal of Steroid Biochemistry and Molecular Biology 85 469-472.
3. Aragon M, Mastrocola R, Brignardello E, Catalano M, Robino G, Manti R, Parola M, Danni O & Boccuzzi G 2002 Dehydroepiandrosterone modulates nuclear factor-κB activation in hippocampus of diabetic rats. Endocrinology 143 3250-3258.
4. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB et al. 2003 Diagnosis and complications of Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 88 5593-5602.
5. Aziz MH, Ghotra AS, Shukla Y & Ahmad N 2004 Ultraviolet-B radiation causes an upregulation of survivin in human keratinocytes and mouse skin. Photochemistry and Photobiology 80 602-608.
6. Barnes PJ & Karin M 1997 Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. New England Journal of Medicine 336 1066-1071.
7. Baulieu EE 1996 Dehydroepiandrosterone (DHEA): a fountain of youth? Journal of Clinical Endocrinology and Metabolism 81 3147-3151.
8. Chang LL, Wun WS, Ho LL & Wang PS 2003 Effects of dehydroepiandrosterone on corticosterone release in rat zona fasciculata-reticularis cells. Naunyn Schmiedeberg's Archive of Pharmacology 368 487-495.
9. Curry EA, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, O'Connell M & Sweeney CJ 2004 Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs 22 299-305.
10. Ebeling P & Koivisto VA 1994 Physiological importance of dehydroepiandrosterone. Lancet 343 1479-1481.
11. Gao J, Sun HY, Zhu ZR, Ding Z & Zhu L 2005 Antioxidant effects of dehydroepiandrosterone are related to up-regulation of thioredoxin in SH-SY5Y cells. Acta Biochimica et Biophysica Sinica 37 119-125.
12. Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A & Wilson CB 2004 Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism 89 6348-6357.
13. Heaney AP, Fernando M, Yong WH & Melmed S 2002 Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nature Medicine 8 1281-1287.
14. Heaney AP, Fernando M & Melmed S 2003 PPAR-γ receptor ligands: novel therapy for pituitary adenomas. Journal of Clinical Investigation 111 1381-1388.
15. Horiguchi Y, Kuroda K, Nakashima J, Murai M & Umezawa K 2003 Antitumor effect of a novel nuclear factor-κB activation inhibitor in bladder cancer cells. Expert Review of Anticancer Therapy 3 793-798.
16. Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M & Nakashima N 2004 Dehydroepiandrosterone-sulfate inhibits nuclear factor-κB-dependent transcription in hepatocytes, possibly through antioxidant effect. Journal of Clinical Endocrinology and Metabolism 89 3449-3454.
17. Kabe Y, Ando K, Hirao S, Yoshida M & Handa H 2005 Redox regulation of NF-κB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxidants and Redox Signaling 7 395-403.
18. Kawakami H, Tomita M, Matsuda T, Ohta T, Tanaka Y, Fujii M, Hatano M, Tokuhisa T & Mori N 2005 Transcriptional activation of survivin through the NF-κB pathway by human T-cell leukemia virus type I tax. International Journal of Cancer 115 967-974.
19. Kochan Z & Karbowska J 2004 Dehydroepiandrosterone up-regulates resistin gene expression in white adipose tissue. Molecular and Cellular Endocrinology 218 57-64.
20. Kovalovsky D, Paez Pereda M, Labeur M, Renner U, Holsboer F, Stalla GK & Arzt E 2004 Nur77 induction and activation are necessary for interleukin-1 stimulation of proopiomelanocortin in AtT-20 corticotrophs. FEBS Letters 563 229-233.
21. Kwok BH, Koh B, Ndubuisi MI, Elofsson M & Crews CM 2001 The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IκB kinase. Chemistry and Biology 8 759-766.
22. LaCasse EC, Baird S, Korneluk RG & MacKenzie AE 1998 The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 3247-3259.
23. Liang J, Yao G, Yang L & Hou Y 2004 Dehydroepiandrosterone induces apoptosis of thymocyte through Fas/Fas-L pathway. International Immunopharmacology 4 1467-1475.
24. Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer JM, Lee EJ, Jameson JL, Jordan VC & Cryns VL 2005 Peroxisome proliferator-activated receptor γ agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. Journal of Biological Chemistry 280 6742-6751.
25. Miller WL 2002 Androgen biosynthesis from cholesterol to DHEA. Molecular and Cellular Endocrinology 198 7-14.
26. Nakshatri H, Rice SE & Bhat-Nakshatri P 2004 Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c Jun N-terminal kinase. Oncogene 23 7330-7344.
27. Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C et al. 2001 Retinoic acid prevents experimental Cushing syndrome. Journal of Clinical Investigation 108 1123-1131.
28. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr, Sledge GW Jr et al. 2000 Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 19 4159-4169.
29. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E & Ben-Neriah Y 2004 NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431 461-466.
30. Riggins RB, Zwart A, Nehra R & Clarke R 2005 The nuclear factor κB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Molecular Cancer Therapy 4 33-41.
31. Ross JJ, Arnason JT & Birnboim HC 1999 Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Medica 65 126-129.
32. Salvesen GS & Duckett CS 2002 IAP proteins: blocking the road to death's door. Nature Reviews in Molecular and Cellular Biology 3 401-410.
33. Schimmer AD 2004 Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Research 64 7183-7190.
34. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW & Chen CS 2005 Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR γ. Cancer Research 65 1561-1569.
35. Swana HS, Grossman D, Anthony JN, Weiss RM & Altieri DC 1999 Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. New England Journal of Medicine 341 452-453.
36. Umezawa K & Chaicharoenpong C 2002 Molecular design and biological activities of NF-κB inhibitors. Molecules and Cells 14 163-167.
37. Villareal DT & Holloszy JO 2004 Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. Journal of the American Medical Association 292 2243-2248.
38. Widstrom RL & Dillon JS 2004 Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate? Seminars in Reproductive Medicine 22 289-298.
39. Yang L, Cao Z, Yan H & Wood WC 2003 Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Research 63 6815-6824.
40. Yang NC, Jeng KC, Ho WM, Chou SJ & Hu ML 2000 DHEA inhibits cell growth and induces apoptosis in BV-2 cells and the effects are inversely associated with glucose concentration in the medium. Journal of Steroid Biochemistry and Molecular Biology 75 159-166.